MMP2 and Parkinson disease: SB-3CT, a selective MMP2/9 inhibitor, has been shown to mitigate rotenone-induced cognitive deficits in mice by targeting microglia-mediated blood–brain barrier disruption and neuronal apoptosis via MMP2/9, highlighting its mechanistic relevance to PD pathogenesis [28].